David Hastings joins Incyte as executive vice president and chief financial officer, replacing John Vuko, the Palo Alto, Calif., and Wilmington, Del., company said last week. Hastings comes to Incyte from ArQule, where he has served as CFO and treasurer since 2000. Before joining ArQule, Hastings was vice president and corporate controller of Genzyme, and prior to that, was director of finance at Sepracor. Vuko, who has been Incyte’s CFO since December 1999, will remain as an advisor to Incyte “for a period of time,” the company said in a statement.
Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue in an advisory capacity until the end of the year, the company said last week. Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research, of which he was president and CEO. The resignation of Trevisan, which the company said was by “mutual agreement of the parties,” comes as Gene Logic moves to fully integrate Therimmune Research under the Gene Logic brand name. Trevisan founded TherImmune in December 1998. Prior to this, he was president of Perot Systems Communications, which does billing systems for the telecommunications industry, and before that, was president and CEO of CommSys, an outsource billing provider. Trevisan also founded National Clinical Resarch Centers and was head of strategic business development at Pansophic systems.
Karen Dawes has joined the board of directors of Genaissance Pharmaceuticals, the New Haven, Conn., company said last week. Dawes is principal at the consulting group Knowledgeable Decisions, which focuses on biotech and emerging pharma companies. Previously, she worked as senior vice president and US Business group head at Bayer. She has also worked at Wyeth Pharmaceuticals, Genetics Institute, and Pfizer. She on the board of Protein Design Labs.
Darlene Solomon has been named vice president and director of Agilent Laboratories, replacing the retiring Tom Saponas, the company said. Solomon is on advisory boards for the National Science Foundation’s Nanobiotechnology Center and the Defense Advanced Research Projects Agency Center for Biochemical Optoelectronic Microsystems.